Adlai Nortye Group (ANL) vs Bicara Therapeutics (BCAX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Adlai Nortye Group (ANL) has outperformed Bicara Therapeutics (BCAX) over the past year, gaining 796.5% versus a loss of 4.1%. Bicara Therapeutics is the larger company by market cap ($1.14 billion vs $998.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANL | BCAX |
|---|---|---|
| Share price | $15.51 | $17.26 |
| Market cap | $998.81M | $1.14B |
| 1-day change | +10.39% | +5.12% |
| YTD return | +992.25% | +2.55% |
| 1-year return | +796.53% | -4.11% |
| EPS (TTM) | $-0.66 | $-3.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.25 | $30.99 |
| 52-week low | $0.879 | $13.70 |
| Distance from 52-week high | -10.09% | -44.30% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +90.20% | +105.68% |
| Average volume | 187.30K | 623.17K |
| Shares outstanding | 58.73M | 66.17M |
| Employees | 109 | 103 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANL has outperformed BCAX by 800.6 percentage points over the past year.
About Adlai Nortye Group
ANL stock →Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies.
Healthcare · Biotechnology · 109 employees
About Bicara Therapeutics
BCAX stock →Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors.
Healthcare · Biotechnology · 103 employees
ANL vs BCAX FAQ
Which is bigger, Adlai Nortye Group or Bicara Therapeutics?
Bicara Therapeutics (BCAX) is larger, with a market capitalization of $1.14B compared with $998.81M for Adlai Nortye Group (ANL).
Which stock has performed better over the past year, ANL or BCAX?
ANL returned +796.53% over the past 12 months, compared with -4.11% for BCAX (price return, excluding dividends). Past performance does not predict future results.
Are Adlai Nortye Group and Bicara Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.